The following is a summary of the Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Aytu reported an ADHD portfolio revenue growth of 49% in comparison to the fiscal 2023 third quarter.

• The company's adjusted EBITDA has improved by $7 million compared to the third quarter of the previous year.

• Trailing 12-month firm-wide adjusted EBITDA is above $15 million, while the operating income over the same period for the Rx business is above $7 million.

• Cash balance remained consistent at $19.8 million, compared to $19.5 million at the end of the December quarter.

Business Progress:

• Aytu reported constant growth in its ADHD portfolio and is in the process of outsourcing its ADHD brand manufacturing and overall operation improvements.

• A strategic shift towards the prescription medicine business has suspended their clinical development programs, with plans to wind down its consumer health segment by mid-calendar 2024.

• The company is transitioning towards positive net income and free cash flow generation.

• The near future plans include the exit from the consumer health segment, completed ADHD production shift, a steady rebound in the pediatric portfolio revenue, and the refinancing of Aytu's term loan.

• The company is set on improving top-line figures, reducing costs, and focusing on free cash flow and net income. They anticipate to continue posting positive EBITDA, significantly grow revenues, and manage expenses better in fiscal year 2025.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.